Mezzion Pharma Announces $20 Million Funding to Support Udenafil for Fontan Patients' Trials

Mezzion Secures $20 Million to Propel Udenafil Trials



Mezzion Pharma Co., Ltd., a pioneering company in treating rare diseases, has made notable strides by securing approximately $20 million in funding to support its international clinical trial for udenafil, specifically aimed at patients with Fontan circulation. This investment marks a significant step forward in the global Phase 3 FUEL-2 trial, which is anticipated to have a substantial impact on patients suffering from this rare congenital heart condition.

The funding round was spearheaded by prominent investors including Midas-Meritz New Technology Finance Association and KDBC-Korea Investment Securities New Technology Investment Association. Both institutions have expressed strong confidence in Mezzion's ongoing development and strategic initiatives, further underlining the promising potential of the late-stage drug in improving the quality of life for Fontan patients.

"We are thrilled to collaborate with Midas Private Equity and KDBC as we progress through a crucial phase for the development of udenafil," said Dean Park, the Chairman and CEO of Mezzion. He highlighted the dire need for effective treatments in the Fontan population, emphasizing how this funding validates the strength of their clinical data, scientific approach, and the potential influence of its therapies on patients around the world.

Midas PE, known for its strategic investments, manages over $230 million in assets and CEO Lim Chun-soo articulated their positive outlook on the direction of Mezzion. After a comprehensive review of the results from the initial FUEL-1 trial and the emerging protocols for FUEL-2, they are convinced that udenafil is strategically positioned for successful Phase 3 clinical completion and subsequent regulatory approval.

This financing comes at a pivotal time for Mezzion, as an increasing clinical and regulatory momentum is evident. The recent introduction of dedicated ICD-10 codes for conditions associated with the Fontan procedure not only acknowledges the needs of this historically overlooked patient community but also enhances care standards and insurance coverage. Mezzion continues to lead the way in advocating for the treatment of rare congenital heart diseases, reinforcing their long-term commitment to advance therapeutic options in this arena.

Chairman Park observed, "With rising enrollment and heightened engagement from clinical sites, we now have time and data working in our favor. The initial $20 million secured is significant, and we are determined to leverage this to attract further investments as we move forward."

About Mezzion Pharma


Mezzion Pharma Co., Ltd. is headquartered in South Korea and publicly traded on the KOSDAQ exchange under the stock number 140410. The company is dedicated to developing innovative treatments for rare and underserved diseases. Their U.S. subsidiary, Mezzion Pharmaceuticals, Inc., located in New Jersey, plays a pivotal role in global clinical development and commercialization efforts. Currently, Mezzion is advancing udenafil through Phase 3 trials, marking it as a first-in-class therapy intended to address the challenges faced by patients with Fontan physiology.

For more details on the endeavors of Mezzion Pharma, including the FUEL-2 study, visit www.mezzion.com and www.FUEL2Study.com.

Contact Information


  • - John Presser, CBO: Email
  • - Mr. Sung-Il Noh, CFO: Email

Topics Health)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.